Aisling Capital Management LP
•CIK: 1766721•Filing: Q4 2025
**Aisling Capital Management LP** is a sophisticated, actively managed fund overseeing $479M across a concentrated portfolio of 13 positions. The strategy exhibits a significant overweighting in biotechnology, anchored by a dominant position in BBIO, representing $389.3M of the fund's assets. Further allocations include substantial stakes in SNDX ($27.7M) and GLUE ($23.1M). This structure indicates a high-conviction, sector-specific approach to generating alpha.
Total AUM
$478.9M
QoQ Performance
+4.9%
Positions
13
Top 10 Concentration
99.6%
Latest Filing
Q4 2025
Top Holdings Allocation
BBIO
SNDX
BBIO81.3%
SNDX5.8%
GLUE4.8%
BCAX2.0%
CMPS1.7%
BBOT1.5%
CALC0.7%
SRRK0.7%
📈 Biggest Buys
—
Urogen Pharma Ltd. (URGN)
NEW
0.5% of portfolio
📉 Biggest Sells
BBIO
BridgeBio Pharma Inc. (BBIO)
-16.4%
81.3% of portfolio
Sector Breakdown
Other100.0%
🚪 Exited Positionssold since Q3 2025
Changes from Q3 2025
NEW1 new position
↓1 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023